{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:25:55Z","timestamp":1791897955514,"version":"4.3.4"},"reference-count":95,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T00:00:00Z","timestamp":1695427200000},"content-version":"am","delay-in-days":387,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013301","name":"Parkinson's Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013301","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008440","name":"International Parkinson and Movement Disorder Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015569","name":"Consortium canadien en neurod\u00e9g\u00e9n\u00e9rescence associ\u00e9e au vieillissement","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015569","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018911","name":"University Hospital Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018911","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009408","name":"Fondation Brain Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009408","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009862","name":"Davis Phinney Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009862","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","prd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism & Related Disorders"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.parkreldis.2022.08.014","type":"journal-article","created":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T00:54:18Z","timestamp":1661302458000},"page":"124-130","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Cannabinoids in movement disorders"],"prefix":"10.1016","volume":"102","author":[{"given":"Benzi M.","family":"Kluger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew P.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6372-6007","authenticated-orcid":false,"given":"Janis M.","family":"Miyasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.parkreldis.2022.08.014_bib2","first-page":"180","article-title":"Medicinal cannabis: history, pharmacology, and implications for the acute care setting","volume":"42","author":"Bridgeman","year":"2017","journal-title":"P T"},{"issue":"3","key":"10.1016\/j.parkreldis.2022.08.014_bib1","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/mds.26142","article-title":"The therapeutic potential of cannabinoids for movement disorders","volume":"30","author":"Kluger","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2022.08.014_bib74","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.drugpo.2019.09.001","article-title":"What can we learn from the experiences in Canada, Germany and Thailand?","volume":"74","author":"Rehm","year":"2019","journal-title":"Int. J. Drug Pol."},{"key":"10.1016\/j.parkreldis.2022.08.014_bib75","unstructured":"United Nations Office on Drugs and Crime (UNODC). World Drug Report 2018. Retrieved from https:\/\/www.unodc.org\/wdr2018\/."},{"key":"10.1016\/j.parkreldis.2022.08.014_bib77","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12906-019-2803-2","article-title":"Therapeutic use of cannabis and cannabinoids: an evidence mapping and appraisal of systematic reviews","volume":"20","author":"Monter-Oleas","year":"2020","journal-title":"BMC Complementary Med. Ther."},{"key":"10.1016\/j.parkreldis.2022.08.014_bib88","first-page":"378","article-title":"Systematic review of systematic reviews for medical cannbinoids. Pain, nausea and vomiting, spasticity, and harms","volume":"64","author":"Allan","year":"2018","journal-title":"Can. Fam. Physician"},{"issue":"1","key":"10.1016\/j.parkreldis.2022.08.014_bib68","doi-asserted-by":"crossref","DOI":"10.3390\/geriatrics5010002","article-title":"Cannabinoids in the older person: a literature review","volume":"5","author":"Beedham","year":"2020","journal-title":"Geriatrics"},{"issue":"17","key":"10.1016\/j.parkreldis.2022.08.014_bib76","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1001\/jama.2017.11909","article-title":"Labeling accuracy of cannabidiol extracts sold online","volume":"318","author":"Bonn-Miller","year":"2020","journal-title":"JAMA"},{"issue":"1607","key":"10.1016\/j.parkreldis.2022.08.014_bib3","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.1098\/rstb.2011.0394","article-title":"The evolution and comparative neurobiology of endocannabinoid signalling","volume":"367","author":"Elphick","year":"2012","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"issue":"1607","key":"10.1016\/j.parkreldis.2022.08.014_bib4","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1098\/rstb.2012.0313","article-title":"Endocannabinoids in nervous system health and disease: the big picture in a nutshell","volume":"367","author":"Skaper","year":"2012","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"issue":"3","key":"10.1016\/j.parkreldis.2022.08.014_bib5","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1152\/physrev.00004.2003","article-title":"Role of endogenous cannabinoids in synaptic signaling","volume":"83","author":"Freund","year":"2003","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.parkreldis.2022.08.014_bib6","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/nyas.12068","article-title":"The effects of endocannabinoid signaling on network activity in developing and motor circuits","volume":"1279","author":"Wenner","year":"2013","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"4","key":"10.1016\/j.parkreldis.2022.08.014_bib7","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1152\/physiol.00007.2010","article-title":"The role of endocannabinoid signaling in motor control","volume":"25","author":"El Manira","year":"2010","journal-title":"Physiology"},{"issue":"1","key":"10.1016\/j.parkreldis.2022.08.014_bib8","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/npp.2017.206","article-title":"CB1 receptor signaling in the brain: extracting specificitiy from ubiquity","volume":"43","author":"Busquets-Garcia","year":"2018","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.parkreldis.2022.08.014_bib9","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1177\/0269881111400652","article-title":"CNS effects of CB2 cannabinoid receptors: beyond neuro-immuno-cannabinoid activity","volume":"26","author":"Onaivi","year":"2012","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.parkreldis.2022.08.014_bib10","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.nbd.2014.11.024","article-title":"Activation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats","volume":"74","author":"Martinez","year":"2015","journal-title":"Neurobiol. Dis."},{"issue":"2","key":"10.1016\/j.parkreldis.2022.08.014_bib11","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/phar.1187","article-title":"The pharmacologic and clinical effects of medical cannabis","volume":"33","author":"Borgelt","year":"2013","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.parkreldis.2022.08.014_bib12","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/3-540-26573-2_16","article-title":"Cannabinoid control of motor function at the basal ganglia","volume":"168","author":"Fernandez-Ruiz","year":"2005","journal-title":"Handb. Exp. Pharmacol."},{"issue":"5","key":"10.1016\/j.parkreldis.2022.08.014_bib13","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1038\/npp.2017.12","article-title":"Singular location and signaling profile of adenosine A2A-cannabinoid CB1 receptor heteromers in the dorsal striatum","volume":"43","author":"Moreno","year":"2018","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.parkreldis.2022.08.014_bib14","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-56785-1","article-title":"A novel phytocannabinoid isolated from Cannabis sativa L. with an in vivo cannabimimetic activity higher than \u03949-tetrahydrocannabinol: \u03949-Tetrahydrocannabiphorol","volume":"9","author":"Citti","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.parkreldis.2022.08.014_bib15","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/bs.irn.2018.08.004","article-title":"Molecular imaging of the cannabinoid system in idiopathic Parkinson's disease","volume":"141","author":"Cilia","year":"2018","journal-title":"Int. Rev. Neurobiol."},{"issue":"1","key":"10.1016\/j.parkreldis.2022.08.014_bib17","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/syn.10054","article-title":"Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease","volume":"44","author":"Lastres-Becker","year":"2002","journal-title":"Synapse"},{"issue":"2\u20133","key":"10.1016\/j.parkreldis.2022.08.014_bib18","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0014-2999(02)02477-9","article-title":"Effects of pharmacological manipulations of cannabinoid receptors on severity of dystonia in a genetic model of paroxysmal dyskinesia","volume":"454","author":"Richter","year":"2002","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.parkreldis.2022.08.014_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2019.104646","article-title":"Targeting the cannabinoid receptor CB2 in a mouse model of l-dopa induced dyskinesia","volume":"134","author":"Rentsch","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.parkreldis.2022.08.014_bib20","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.nbd.2016.06.013","article-title":"Co-administration of cannabidiol and capsazepine reduces L-DOPA-induced dyskinesia in mice: possible mechanism of action","volume":"94","author":"Dos-Santos-Pereira","year":"2016","journal-title":"Neurobiol. Dis."},{"issue":"2","key":"10.1016\/j.parkreldis.2022.08.014_bib21","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.bbr.2009.04.035","article-title":"The CB(1) antagonist rimonabant is adjunctively therapeutic as well as monotherapeutic in an animal model of Parkinson's disease","volume":"203","author":"Kelsey","year":"2009","journal-title":"Behav. Brain Res."},{"issue":"1","key":"10.1016\/j.parkreldis.2022.08.014_bib22","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.neulet.2008.04.041","article-title":"Enhanced striatal glutamate release after the administration of rimonabant to 6-hydroxydopamine-lesioned rats","volume":"438","author":"Garcia-Arencibia","year":"2008","journal-title":"Neurosci. Lett."},{"issue":"Pt A","key":"10.1016\/j.parkreldis.2022.08.014_bib23","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.physbeh.2016.06.013","article-title":"Cannabinoid receptor agonism suppresses tremor, cognition disturbances and anxiety-like behaviors in a rat model of essential tremor","volume":"164","author":"Abbassian","year":"2016","journal-title":"Physiol. Behav."},{"issue":"10","key":"10.1016\/j.parkreldis.2022.08.014_bib24","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1038\/s41386-018-0107-8","article-title":"Inhibition of endocannabinoid degradation rectifies motivational and dopaminergic deficits in the Q175 mouse model of Huntington's disease","volume":"43","author":"Covey","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.parkreldis.2022.08.014_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107808","article-title":"Cannabidiol increases the nociceptive threshold in a preclinical model of Parkinson's disease","volume":"163","author":"Crivelaro do Nascimento","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.parkreldis.2022.08.014_bib90","article-title":"Cannabinoids induce apathetic and impulsive patterns of choice through CB1 receptors and TRPV1 channels","volume":"133","author":"Fatahi","year":"2018","journal-title":"Neuorpharmacology"},{"issue":"4","key":"10.1016\/j.parkreldis.2022.08.014_bib91","doi-asserted-by":"crossref","first-page":"e376","DOI":"10.1212\/WNL.0000000000008683","article-title":"Apathy rating scores and \u03b2-amyloidopathy in patients with Parkinson disease at risk for cognitive decline","volume":"94","author":"Zhou","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2022.08.014_bib92","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/B978-0-444-64012-3.00007-1","article-title":"Neuropsychiatric aspects of Parkinson disease psychopharmacology: insights from circuit dynamics","volume":"165","author":"Butula","year":"2019","journal-title":"Handb. Clin. Neurol."},{"key":"10.1016\/j.parkreldis.2022.08.014_bib93","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.pbb.2018.05.012","article-title":"Examination of the effects of cannabinoid ligands on decision making in rat gambling task","volume":"170","author":"Ferland","year":"2018","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.parkreldis.2022.08.014_bib94","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.neuropharm.2017.04.018","article-title":"Mechanisms contributing to cognitive deficits in cannabis users","volume":"124","author":"Mizrahi","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.parkreldis.2022.08.014_bib26","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/bs.irn.2019.06.012","article-title":"Therapeutic potential of cannabinoids as neuroprotective agents for damaged cells conducing to movement disorders","volume":"146","author":"Antonazzo","year":"2019","journal-title":"Int. Rev. Neurobiol."},{"issue":"1","key":"10.1016\/j.parkreldis.2022.08.014_bib27","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s12035-007-0004-3","article-title":"Cannabinoids and neuroprotection in basal ganglia disorders","volume":"36","author":"Sagredo","year":"2007","journal-title":"Mol. Neurobiol."},{"issue":"1","key":"10.1016\/j.parkreldis.2022.08.014_bib28","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.brainres.2006.11.063","article-title":"Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties","volume":"1134","author":"Garcia-Arencibia","year":"2007","journal-title":"Brain Res."},{"issue":"5","key":"10.1016\/j.parkreldis.2022.08.014_bib29","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nri1602","article-title":"Cannabinoid-based drugs as anti-inflammatory therapeutics","volume":"5","author":"Klein","year":"2005","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.parkreldis.2022.08.014_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/antiox9010021","article-title":"Antioxidative and anti-inflammatory properties of cannabidiol","volume":"9","author":"Atalay","year":"2019","journal-title":"Antioxidants"},{"key":"10.1016\/j.parkreldis.2022.08.014_bib31","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.pharmthera.2016.06.011","article-title":"Microglia activation states and cannabinoid system: therapeutic implications","volume":"166","author":"Mecha","year":"2016","journal-title":"Pharmacol. Ther."},{"issue":"Pt 1","key":"10.1016\/j.parkreldis.2022.08.014_bib32","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/brain\/awq278","article-title":"Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease","volume":"134","author":"Blazquez","year":"2011","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.parkreldis.2022.08.014_bib110","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/j.1476-5381.2010.00773.x","article-title":"Neuroprotective potential of CB1 receptor agonists in an in vitro model of Huntington's disease","volume":"160","author":"Scotter","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.parkreldis.2022.08.014_bib111","article-title":"Cannabinoids and pain: new insights from old molecules","volume":"9","author":"Vucetic","year":"2018","journal-title":"Front. Pharmacol."},{"issue":"11","key":"10.1016\/j.parkreldis.2022.08.014_bib47","article-title":"Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study","volume":"57","author":"Sieradzan","year":"2001","journal-title":"Brief Communications"},{"key":"10.1016\/j.parkreldis.2022.08.014_bib46","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/00002826-200405000-00003","article-title":"Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease","volume":"27","author":"Mesnage","year":"2004","journal-title":"Pharmacol.Clin. Neuropharmacol."},{"key":"10.1016\/j.parkreldis.2022.08.014_bib42","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1212\/01.WNL.0000140288.48796.8E","article-title":"Cannabis for dyskinesia in Parkinson disease. A randoized double-blind crossover study","volume":"63","author":"Carroll","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2022.08.014_bib50","first-page":"1088","article-title":"Effects of cannabidiol in the treatment of patients with Parkinson's isease: an exploratory double-blind trial","volume":"28","author":"Chagas","year":"2014","journal-title":"J Psychoparacol"},{"key":"10.1016\/j.parkreldis.2022.08.014_bib105","article-title":"Cannabis and its derivatives for the use of motor symptoms in Parkinson's disease: a systematic review and meta-analysis","volume":"14 17562864211018561","author":"Thanabalasingam","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"8","key":"10.1016\/j.parkreldis.2022.08.014_bib57","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1177\/0269881108096519","article-title":"Cannabidiol for the treatment of psychosis in Parkinson's disease","volume":"23","author":"Zuardi","year":"2009","journal-title":"J. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.parkreldis.2022.08.014_bib55","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/jcpt.12179","article-title":"Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson's disease patients: a case series","volume":"39","author":"Chagas","year":"2014","journal-title":"J. Clin. Pharm. Therapeut."},{"issue":"2","key":"10.1016\/j.parkreldis.2022.08.014_bib82","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/0269881119895536","article-title":"Effects of acute cannabidiol administration on anxiety and tremors induced by a simulated public speaking test in patients with Parkinson's disease","volume":"34","author":"Martins de Faria","year":"2020","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.parkreldis.2022.08.014_bib78","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ejp.942","article-title":"Effect of medical cannabis on thermal quantittive measureents of pain in patients with Parkinson's disease","volume":"21","author":"Shohet","year":"2017","journal-title":"Eur. J. Pain"},{"issue":"4","key":"10.1016\/j.parkreldis.2022.08.014_bib103","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/ana.25864","article-title":"Non-motor symptoms in Parkinson's disease are reduced by nabilone","volume":"88","author":"Peball","year":"2020","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.parkreldis.2022.08.014_bib54","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00406-019-00982-6","article-title":"Is cannabidiol the ideal drug to treat non-motor Parkinson's disease symptoms?","volume":"269","author":"Crippa","year":"2019","journal-title":"Eur. Arch. Psychiatr. Clin. Neurosci."},{"key":"10.1016\/j.parkreldis.2022.08.014_bib104","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.parkreldis.2020.06.033","article-title":"Cannabis in patients with Parkinson's disease in Argentina. A cross sectional study","volume":"78","author":"Micheli","year":"2020","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.parkreldis.2022.08.014_bib33","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/874849","article-title":"Self-reported efficacy of cannabis and other complementary medicine modalities by Parkinson's disease patients in Colorado","volume":"2015","author":"Finseth","year":"2015","journal-title":"Evid Based Complement Alternat Med."},{"issue":"1","key":"10.1016\/j.parkreldis.2022.08.014_bib56","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s11325-019-01978-1","article-title":"More evidence of cannabis efficacy in restless legs syndrome","volume":"24","author":"Ghorayeb","year":"2020","journal-title":"Sleep Breath."},{"key":"10.1016\/j.parkreldis.2022.08.014_bib79","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/0091-3057(91)90386-G","article-title":"Controlled clinical trial of cannabidiol in Huntington's disease","volume":"40","author":"Consroe","year":"1991","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.parkreldis.2022.08.014_bib80","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1002\/mds.22809","article-title":"A pilot study using nabilone for symptomatic treatment in Huntington's disease","volume":"24","author":"Curtis","year":"2009","journal-title":"Mov. Disord."},{"issue":"2","key":"10.1016\/j.parkreldis.2022.08.014_bib39","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3233\/JHD-170283","article-title":"Cannabinoids for treatment of dystonia in huntington's disease","volume":"7","author":"Saft","year":"2018","journal-title":"J. Huntingtons Dis."},{"key":"10.1016\/j.parkreldis.2022.08.014_bib81","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1007\/s00415-016-8145-9","article-title":"A double-blind randomized, cross-over, placebo-controlled pilot trial with Sativex in Huntington's disease","volume":"263","author":"Lopez-Sendon Moreno","year":"2016","journal-title":"J. Neurol."},{"issue":"4","key":"10.1016\/j.parkreldis.2022.08.014_bib53","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1176\/jnp.2006.18.4.553","article-title":"Nabilone could treat chorea and irritability in Huntington's disease","volume":"18","author":"Curtis","year":"2006","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"issue":"2","key":"10.1016\/j.parkreldis.2022.08.014_bib83","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1055\/s-2002-25028","article-title":"Treatment of Tourette's Syndrome with \u03949-Tetrahydrocannabinol (THC): a randomized crossover trial","volume":"35","author":"Muller-Vahl","year":"2002","journal-title":"Pharmacopsychiatry"},{"issue":"4","key":"10.1016\/j.parkreldis.2022.08.014_bib52","doi-asserted-by":"crossref","first-page":"459","DOI":"10.4088\/JCP.v64n0417","article-title":"\u03949-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial","volume":"64","author":"Muller-Vahl","year":"2003","journal-title":"J. Clin. Psychiatr."},{"issue":"2","key":"10.1016\/j.parkreldis.2022.08.014_bib69","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/sj.npp.1300047","article-title":"Treatment of Tourette syndrome with \u0394-9-tetrahydrocannabinol (\u03b49-THC): no influence on neuropsychological performance","volume":"28","author":"Muller-Vahl","year":"2003","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.parkreldis.2022.08.014_bib38","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1176\/appi.neuropsych.16110310","article-title":"Preliminary evidence on cannabis effectiveness and tolerability for adults with tourette syndrome","volume":"29","author":"Abi-Jaoude","year":"2017","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"issue":"1","key":"10.1016\/j.parkreldis.2022.08.014_bib51","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/mds.1280","article-title":"Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia","volume":"17","author":"Fox","year":"2002","journal-title":"Mov. Disord."},{"issue":"4","key":"10.1016\/j.parkreldis.2022.08.014_bib36","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3109\/00207458608985678","article-title":"Open label evaluation of cannabidiol in dystonic movement disorders","volume":"30","author":"Consroe","year":"1986","journal-title":"Int. J. Neurosci."},{"key":"10.1016\/j.parkreldis.2022.08.014_bib40","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.parkreldis.2018.09.031","article-title":"TSFM mutations cause a complex hyperkinetic movement disorder with strong relief by cannabinoids","volume":"60","author":"Traschutz","year":"2019","journal-title":"Park. Relat. Disord."},{"issue":"1","key":"10.1016\/j.parkreldis.2022.08.014_bib41","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/mds.20268","article-title":"Cannabis sativa and dystonia secondary to Wilson's disease","volume":"20","author":"Uribe Roca","year":"2005","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2022.08.014_bib58","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejim.2018.01.003","article-title":"The therapeutic effects of cannabis and cannabinoids: an update from the national academies of sciences, engineering and medicine report","volume":"49","author":"Abrams","year":"2018","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.parkreldis.2022.08.014_bib59","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.neuro.2019.08.002","article-title":"Cannabidiol (CBD) use in psychiatric disorders: a systematic review","volume":"74","author":"Bonaccorso","year":"2019","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.parkreldis.2022.08.014_bib100","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.jagp.2019.05.002","article-title":"Randomized placebo-controlled trial of nabilone for agitation in Alzheimer's disease","volume":"27","author":"Herrmann","year":"2019","journal-title":"Am. J. Geriatr. Psychiatr."},{"issue":"6","key":"10.1016\/j.parkreldis.2022.08.014_bib109","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/npp.2011.6","article-title":"Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-na\u00efve social phobia patients","volume":"36","author":"Bergamaschi","year":"2011","journal-title":"Neuropsychopharmacology : official publication of the American College of"},{"key":"10.1016\/j.parkreldis.2022.08.014_bib84","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.pnpbp.2017.10.010","article-title":"Chronic pain and pain processing in Parkinson's disease","volume":"87","author":"Blanchet","year":"2018","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.parkreldis.2022.08.014_bib85","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.parkreldis.2019.06.009","article-title":"Pain in cervical dystonia: evidence of abnormal inhibitory control","volume":"65","author":"Tinazzi","year":"2019","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.parkreldis.2022.08.014_bib86","article-title":"Cannabis-based medicines for chronic neuropathic pain in adults (Review)","volume":"3","author":"Mucke","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.parkreldis.2022.08.014_bib89","series-title":"Accelerating Change Transformation Team for the Alberta Medical Association towards Optimized Practice","year":"2018"},{"issue":"12","key":"10.1016\/j.parkreldis.2022.08.014_bib60","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.2105\/AJPH.2007.125849","article-title":"Effects of the national youth anti-drug media campaign on youths","volume":"98","author":"Hornik","year":"2008","journal-title":"Am. J. Publ. Health"},{"issue":"2","key":"10.1016\/j.parkreldis.2022.08.014_bib61","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.mayocp.2011.10.003","article-title":"Blurred boundaries: the therapeutics and politics of medical marijuana","volume":"87","author":"Bostwick","year":"2012","journal-title":"Mayo Clin. Proc."},{"issue":"3","key":"10.1016\/j.parkreldis.2022.08.014_bib62","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.jaac.2016.12.014","article-title":"Evidence for the risks and consequences of adolescent cannabis exposure","volume":"56","author":"Levine","year":"2017","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.parkreldis.2022.08.014_bib99","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.biopsych.2015.12.002","article-title":"Acute and chronic effects of cannabinoids on human cognition \u2013 a systematic review","volume":"79","author":"Broyd","year":"2016","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.parkreldis.2022.08.014_bib97","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1007\/s00213-016-4383-x","article-title":"Acute and chronic effects of cannabinoids on effort-related decision-making and reward learning: an evaluation of the cannabis \u2018amotivational\u2019 hypothesis","volume":"233","author":"Lawn","year":"2016","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.parkreldis.2022.08.014_bib66","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40621-019-0213-z","article-title":"State marijuana laws and opioid overdose mortality","volume":"6","author":"Chihuri","year":"2019","journal-title":"Inj Epidemiol"},{"issue":"5","key":"10.1016\/j.parkreldis.2022.08.014_bib63","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/nrn.2016.28","article-title":"Keep off the grass? Cannabis, cognition and addiction","volume":"17","author":"Curran","year":"2016","journal-title":"Nat. Rev. Neurosci."},{"issue":"4","key":"10.1016\/j.parkreldis.2022.08.014_bib64","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1007\/s11481-018-9782-9","article-title":"Cannabis addiction and the brain: a review","volume":"13","author":"Zehra","year":"2018","journal-title":"J. Neuroimmune Pharmacol."},{"key":"10.1016\/j.parkreldis.2022.08.014_bib102","article-title":"Prevalence of cannabis withdrawal symptoms among people with regular or dependent use of cannabinoids","volume":"3","author":"Bahji","year":"2020","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.parkreldis.2022.08.014_bib65","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1001\/jamapsychiatry.2015.3278","article-title":"Effects of cannabis use on human behavior, including cognition, motivation, and psychosis: a review","volume":"73","author":"Volkow","year":"2016","journal-title":"JAMA Psychiatr."},{"key":"10.1016\/j.parkreldis.2022.08.014_bib95","doi-asserted-by":"crossref","first-page":"531","DOI":"10.7326\/M18-2809","article-title":"Acute illness associated with cannabis use by route of exposure. An observational study","volume":"170","author":"Monte","year":"2019","journal-title":"Ann. Intern. Med."},{"issue":"1\u201313","key":"10.1016\/j.parkreldis.2022.08.014_bib101","article-title":"A systematic review of adverse events arising from the use of synthetic cannabinoids and their assiciated treatment","volume":"54","author":"Tait","year":"2016","journal-title":"Clin. Toxicol."},{"issue":"6","key":"10.1016\/j.parkreldis.2022.08.014_bib67","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1038\/nm.4311","article-title":"A chronic low dose of \u03949-tetrahydrocannabinol (THC) restores cognitive function in old mice","volume":"23","author":"Bilkei-Gorzo","year":"2017","journal-title":"Nat. Med."},{"issue":"Suppl 2","key":"10.1016\/j.parkreldis.2022.08.014_bib72","doi-asserted-by":"crossref","first-page":"S249","DOI":"10.1007\/s00415-010-5741-y","article-title":"A brief history of levodopa","volume":"257","author":"Hornykiewicz","year":"2010","journal-title":"J. Neurol."},{"key":"10.1016\/j.parkreldis.2022.08.014_bib70","doi-asserted-by":"crossref","DOI":"10.1001\/jamainternmed.2019.0677","article-title":"Anticholinergic drug exposure and the risk of dementia: a nested case-control study","author":"Coupland","year":"2019","journal-title":"JAMA Intern. Med."},{"issue":"2","key":"10.1016\/j.parkreldis.2022.08.014_bib71","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s40261-018-0721-6","article-title":"A literature review of psychotropic medications and alcohol as risk factors for falls in community dwelling older adults","volume":"39","author":"Laberge","year":"2019","journal-title":"Clin. Drug Invest."}],"container-title":["Parkinsonism & Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135380202200270X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135380202200270X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:25:58Z","timestamp":1761179158000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S135380202200270X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":95,"alternative-id":["S135380202200270X"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2022.08.014","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cannabinoids in movement disorders","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2022.08.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}